| View |
|
BR-1455
|
Respiratory Syncytial Virus Vaccine (Recombinant, Adjuvanted)
|
Arexvy
|
120 mcg
|
Powder for Suspension for Injection (IM)
|
Prescription Drug (RX)
|
See packaging on the reverse side.
|
-
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
|
GlaxoSmithKline Philippines, Inc.
|
GlaxoSmithKline Philippines, Inc.
|
Monitored Release (MR)
|
22 November 2023
|
22 November 2028
|
| View |
|
BR-1456
|
Insulin Aspart
|
Kirsty
|
100 Units/mL (equivalent to 3.5 mg/mL)
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
USP Type I glass vial with bromobutyl rubber stopper sealed with aluminum flip-off seal x 10 mL (Box of 1's).
|
-
|
Biocon Sdn BHD
|
Malaysia
|
N/A
|
Viatris Pharmaceuticals, Inc.
|
Viatris Pharmaceuticals, Inc.
|
Initial
|
28 November 2023
|
28 November 2028
|
| View |
|
BR-1457
|
Insulin Aspart
|
Kirsty
|
100 Units/mL (equivalent to 3.5 mg/mL)
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
USP Type I glass cartridge with dark grey plunger
stopper and aluminum seal integrated into a pen injector x 3 mL (Box of 5's).
|
-
|
Biocon Sdn BHD
|
Malaysia
|
N/A
|
Viatris Pharmaceuticals, Inc.
|
Viatris Pharmaceuticals, Inc.
|
Initial
|
28 November 2023
|
28 November 2028
|
| View |
|
BR-1452
|
Pneumococcal Polysaccharide Conjugate Vaccine, 13-
Valent (Adsorbed)
|
Pneumocon 13
|
Each dose (0.5 mL) contains the capsular polysaccharide of the following Streptococcus pneumoniae serotypes: Pneumococcal Polysaccharide Serotype 6B
Pneumococcal Polysaccharide Serotype 18C
Pneumococcal Polysaccharide Serotype 4, 23F
Pneumococcal Polysaccharide Serotype 7F Pneumococcal Polysaccharide Serotype 14, 19F Pneumococcal Polysaccharide Serotype 1, 19A Pneumococcal Polysaccharide Serotype 3, 5, 6A, 9V
Conjugated to Tetanus Toxoid carrier protein
6.0 με
3.25 μg
3.0 με
2.85 μg
2.75 μg
2.6 μg
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL borosilicate glass vial with chlorinated butyl rubber stopper and combined aluminum-plastic cap (Box of 20's)
|
-
|
Yuxi Walvax Biotechnology Co., Ltd.
|
China
|
N/A
|
2 World Traders Inc.
|
2 World Traders Inc.
|
Monitored Release (MR) [Reapplication]
|
03 November 2023
|
03 November 2028
|
| View |
|
BR-1458
|
Tremelimumab
|
Imjudo
|
300 mg/15 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Prescription Drug (RX)
|
Type I clear, colorless, glass vial with butyl elastomer stopper and aluminum seal with dark blue flip-off button x 15 mL (Box of 1's).
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
AstraZeneca AB
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
Monitored Release
|
20 December 2023
|
20 December 2028
|
| View |
|
BR-1459
|
Tremelimumab
|
Imjudo
|
25 mg/1.25 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Prescription Drug (RX)
|
Type I clear, colorless, glass vial with butyl elastomer stopper and aluminum seal with violet flip-off button x 1.25 mL (Box of 1's)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
AstraZeneca AB
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
Monitored Release
|
20 December 2023
|
20 December 2028
|
| View |
|
BR-1460
|
Infliximab
|
Remsima
|
120 mg
|
Solution For Injection
|
Prescription Drug (RX)
|
One (1) single use pre-filled pen (1 mL-net content) and
two (2) alcohol swabs in a box.
|
Immunosuppressant
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Celltrion Healthcare Philippines, Inc.
|
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1461
|
Ocrelizumab
|
Ocrevus
|
300 mg/10 ml (30 mg/ml)
|
oncentrate for Solution for
Intravenous Infusion
|
Prescription Drug (RX)
|
15 mL-capacity Type I colorless glass vial with a 20 gray rubber stopper crimped with a 20 aluminium seal fitted with a plastic green flip-off cap x 10 mL- net content (Box of 1's)
|
Selective Immunosuppresant
|
F. Hoffmann-La Roche Ltd.
|
Switzerland
|
|
Roche (Philippines), Inc.
|
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1462
|
Ocrelizumab
|
Ocrevus
|
300 mg/10 ml (30 mg/ml)
|
Concentrate for Solution for
Intravenous Infusion.
|
Prescription Drug (RX)
|
15 mL colorless USP/Ph. Eur./JP Type I glass vial with a 20 mm rubber stopper laminated with fluororesin film, which is crimped with a 20 mm aluminum seal fitted with a plastic flip-off cap
|
Selective Immunosuppresant
|
Roche Diagnostics GmbH
|
Germany
|
|
Roche (Philippines), Inc.
|
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1463
|
Trastuzumab
|
Hertumab
|
150 mg
|
Powder for Concentrate for Solution for Infusion.
(IV)
|
Prescription Drug (RX)
|
20 mL Type I glass vial with bromobutyl rubber stopper and aluminum-plastic combination cap (Box of 1's)
|
-
|
Shanghai Henlius Biopharmaceutical Co., Ltd.
|
China
|
N/A
|
Globo Asiatico Enterprises, Inc.
|
Globo Asiatico Enterprises, Inc.
|
Initial
|
04 January 2024
|
04 January 2029
|
| View |
|
BR-1464
|
Trastuzumab deruxtecan
|
Enhertu
|
100 mg
|
Powder for Concentrate for Solution for Infusion (IV)
|
Prescription (Rx) Drug
|
Type I amber glass vial and sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/ aluminum yellow flip-off crimp cap (Box of 1 vial)
|
Human Epidermal Growth Factor Receptor 2 (HER2)
Inhibitor
|
Baxter Oncology GmbH
|
Germany
|
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
|
Monitored Release
|
15 January 2024
|
15 January 2029
|
| View |
|
BR-1465
|
Japanese Encephalitis Vaccine (Inactivated, Adsorbed)
|
Jeev
|
6 mcg/0.5 mL
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 3 mL USP Type 1 glass vial with grey
bromobutyl rubber stopper, scarlet red aluminum-flip-off seal, and Vaccine Vial Monitor 14 (VVM14) [Box of 48's].
|
Vaccines
|
Biological E. Limited
|
India
|
|
IP Biotech, Inc.
|
IP Biotech, Inc.
|
Monitored Release (MR) [Reapplication]
|
08 February 2024
|
08 February 2029
|
| View |
|
BR-1466
|
Anifrolumab
|
Saphnelo
|
300 mg/2 mL (150 mg/ml)
|
Concentrate for Solution for
Infusion (IV)
|
Prescription Drug (RX)
|
2 mL net content Type I clear and colorless glass vial, sealed with tefloncoated chlorobutyl elastomer stopper. and secured by aluminium seal with flip-off plastic button (Box of 1 vial)
.
|
Monoclonal Antibody.
|
AstraZeneca Nijmegen B.V.
|
Netherlands
|
|
AstraZeneca Pharmaceuticals (Phils.), Inc.
|
|
Monitored Release
|
14 February 2024
|
14 February 2029
|
| View |
|
BR-1467
|
Avelumab
|
Bavencio
|
200 mg/10 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Prescription Drug (RX)
|
200 mg/10 mL (20 mg/mL)
|
Monoclonal Antibodies
|
Merck Serono SA
|
Switzerland
|
|
Merck, Inc.
|
Merck, Inc.
|
Monitored Release (MR)
|
22 February 2024
|
22 February 2029
|
| View |
|
BR-1468
|
Semaglutide
|
Wegovy
|
0.25 mg/0.37 mL (0.68 mg/mL)
|
Solution
Injection (SC)
|
Prescription Drug (RX)
|
Multiple dose. 1.5 mL Type I colourless glass cartridge with chlorobutyl rubber plunger, and aluminum cap with laminated rubber disc, assembled in a PDS290 pen-injector + 4 NovoFine® Plus 32G x 4 mm needles (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1469
|
Semaglutide
|
Wegovy
|
2.4 mg/ 0.75 mL (3.2 mg/mL)
|
Solution for
Injection (SC)
|
Prescription Drug (Rx)
|
Multiple dose. 3 mL Type I colourless glass cartridge with chlorobutyl rubber plunger, and aluminum cap with laminated rubber disc, assembled in a PDS290 pen-injector + 4 NovoFine® Plus 32G x 4 mm needles (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1470
|
Semaglutide
|
Wegovy
|
0.5 mg/0.37 mL (1.34 mg/mL)
|
Solution for
Injection (SC)
|
Prescription Drug (Rx)
|
Multiple dose. 1.5 mL Type I colourless glass cartridge with chlorobutyl rubber plunger, and aluminum cap with laminated rubber disc, assembled in a PDS290. pen-injector +4 NovoFine® Plus 32G x 4 mm needles (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1471
|
Semaglutide
|
Wegovy
|
1 mg/0.75 mL (1.34 mg/mL)
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
Multiple dose. 3 mL Type I colourless glass cartridge with chlorobutyl rubber plunger, and aluminum cap with laminated rubber disc, assembled in a PDS290 pen-injector + 4 needles (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues.
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1472
|
Semaglutide
|
Wegovy
|
1.7 mg/ 0.75 mL (2.27 mg/mL)
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
Multiple dose. 3 mL Type I colourless glass cartridge with chlorobutyl rubber plunger, and aluminum cap with laminated rubber disc, assembled in a PDS290 pen-injector 4 needles (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
BR-1473_PI_01.pdf
|
BR-1473
|
Semaglutide
|
Wegovy
|
2.4 mg/0.75 mL (3.2 mg/mL)
|
Solution for
Injection (SC)
|
Prescription Drug (Rx)
|
Single dose. 1 mL (Net content: 0.75 mL) Type I glass pre-filled syringe with grey chlorobutyl rubber plunger, four (4) 29G stainless steel needles and polyisoprene rubber Type II rigid needle shield assembled in a pen- injector (Box of 1's).
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release (MR)
|
22 May 2024
|
22 May 2029
|